Literature DB >> 12039987

Downregulation of intestinal cytochrome p450 in chronic renal failure.

Francois A Leblond1, Martin Petrucci, Pierre Dubé, Gilbert Bernier, Alain Bonnardeaux, Vincent Pichette.   

Abstract

Chronic renal failure (CRF) is associated with a decrease in intestinal drug metabolism. The mechanisms remain poorly understood, but one hypothesis involves a reduction in cytochrome P450 levels. This study aimed to investigate the effects of CRF on intestinal cytochrome P450. Two groups of rats were defined, i.e., rats with CRF (induced by 5/6 nephrectomy) and control pair-fed rats. Total cytochrome P450 levels and protein and mRNA expression of cytochrome P450 isoforms, as well as in vitro N-demethylation of erythromycin (a probe for CYP3A activity) and 7-ethoxyresorufin o-deethylase activity (a probe for CYP1A), were assessed in intestinal microsomes. Body weights were similar in the two groups. Creatinine clearance was reduced by 77% (P < 0.001) in CRF rats, compared with control pair-fed animals. Total intestinal cytochrome P450 activity was reduced by 32% (P < 0.001) in CRF rats. CYP1A1 and CYP3A2 protein expression was considerably reduced (>40%, P < 0.001) in rats with CRF. CYP2B1, CYP2C6, and CYP2C11 levels were the same in the two groups. RT-PCR assays revealed marked downregulation of CYP1A1 and CYP3A2 gene expression in CRF rats (P < 0.001). Although intestinal cytochrome P450 levels were reduced in CRF, induction by dexamethasone was present. N-Demethylation of erythromycin and 7-ethoxyresorufin o-deethylase activity were decreased by 25% (P < 0.05) in CRF rats, compared with control rats. In conclusion, CRF in rats is associated with decreases in intestinal cytochrome P450 activity (mainly CYP1A1 and CYP3A2) secondary to reduced gene expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039987     DOI: 10.1097/01.asn.0000017575.50319.77

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  25 in total

1.  Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Corina Becker; Sigrun Unger; Anja Schmidt; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

2.  Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.

Authors:  Hiroyuki Sayama; Hiroaki Takubo; Hiroshi Komura; Motohiro Kogayu; Masahiro Iwaki
Journal:  AAPS J       Date:  2014-06-11       Impact factor: 4.009

Review 3.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

4.  Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.

Authors:  Fenglei Huang; Viktoria Moschetti; Benjamin Lang; Atef Halabi; Marc Petersen-Sylla; Chan-Loi Yong; Mabrouk Elgadi
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

Review 5.  A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Authors:  Thomas D Nolin
Journal:  Semin Dial       Date:  2015-04-08       Impact factor: 3.455

Review 6.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

7.  Basal and inducible CYP1 mRNA quantitation and protein localization throughout the mouse gastrointestinal tract.

Authors:  Shigeyuki Uno; Nadine Dragin; Marian L Miller; Timothy P Dalton; Frank J Gonzalez; Daniel W Nebert
Journal:  Free Radic Biol Med       Date:  2007-11-12       Impact factor: 7.376

8.  Decreased lithium disposition to cerebrospinal fluid in rats with glycerol-induced acute renal failure.

Authors:  Rie Sakae; Atsuko Ishikawa; Tomoko Niso; Yukiko Komori; Tetsuya Aiba; Hiromu Kawasaki; Yuji Kurosaki
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

9.  ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

Authors:  Thomas D Nolin; Reginald F Frye; Phuong Le; Hooman Sadr; Judith Naud; Francois A Leblond; Vincent Pichette; Jonathan Himmelfarb
Journal:  J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 10.121

10.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.